Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed.
MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).
Company Details
- Employees
- 10
- Founded
- -
- Address
- Oxfordlaan 55, Maastricht,limburg 6229,netherlands
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- https://www.mladx.com/
- HQ
- Maastricht, Limburg
Mla Diagnostics Questions
Mla Diagnostics's website is https://www.mladx.com/
Mla Diagnostics's LinkedIn profile is https://nl.linkedin.com/company/mla-diagnostics
Mla Diagnostics has
10 employees.
View email and phone details for 10
employees at Mla Diagnostics.
Mla Diagnostics's industry is
Medical Equipment Manufacturing
Mla Diagnostics's top competitors are
Persuasive Dx,
Microsure,
Preimure,
Kaminari Medical,
Hemeo,
Inbiome,
Itero,
Confocal Nl,
Quriegen,
Cardiomo.
Mla Diagnostics's categories are Medical Equipment Manufacturing
Mla Diagnostics's founding year is 2019
